Edition:
United Kingdom

Gilead Sciences Inc (GILD.OQ)

GILD.OQ on NASDAQ Stock Exchange Global Select Market

67.59USD
15 Feb 2019
Change (% chg)

$1.22 (+1.84%)
Prev Close
$66.37
Open
$66.76
Day's High
$67.68
Day's Low
$66.50
Volume
2,361,836
Avg. Vol
2,748,493
52-wk High
$82.71
52-wk Low
$60.32

Chart for

About

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS),... (more)

Overall

Beta: 1.17
Market Cap(Mil.): $107,268.80
Shares Outstanding(Mil.): 1,305.93
Dividend: 0.52
Yield (%): 2.53

Financials

  GILD.OQ Industry Sector
P/E (TTM): 8.92 69.44 33.70
EPS (TTM): 9.21 -- --
ROI: 27.00 8.92 14.45
ROE: 63.92 10.08 15.96

Gilead misses key goal in NASH liver disease trial, shares sink

CHICAGO Gilead Sciences Inc said on Monday that a late-stage study of a key experimental drug aimed at treating NASH, a progressive fatty liver disease, failed to meet its main goal, sending the company's shares down 4.6 percent in after-hours trading.

11 Feb 2019

Gilead misses key goal in NASH liver disease trial, shares sink

CHICAGO, Feb 11 Gilead Sciences Inc said on Monday that a late-stage study of a key experimental drug aimed at treating NASH, a progressive fatty liver disease, failed to meet its main goal, sending the company's shares down 4.6 percent in after-hours trading.

11 Feb 2019

Gilead fourth-quarter profit misses Wall Street estimate, shares fall

Gilead Sciences Inc on Monday reported a fourth-quarter profit that fell short of Wall Street estimates, sending shares lower, as sales of its flagship hepatitis C treatments continued to slide and it recorded one-time charges, and the company .

04 Feb 2019

UPDATE 2-Gilead 4th-qtr profit misses Wall Street estimate, shares fall

Feb 4 Gilead Sciences Inc on Monday reported a fourth-quarter profit that fell short of Wall Street estimates, sending shares lower, as sales of its flagship hepatitis C treatments continued to slide and it recorded one-time charges, and the company .

04 Feb 2019

Gilead fourth-quarter profit misses Wall Street estimate, shares fall

Feb 4 Gilead Sciences Inc on Monday reported fourth-quarter results that fell short of Wall Street estimates as sales of its flagship hepatitis C drugs continued to slide due to competition for a smaller pool of patients.

04 Feb 2019

Novartis's cancer therapy wins UK backing after initial lymphoma snub

ZURICH Novartis's Kymriah cell therapy won the blessing of health authorities in England for adult lymphoma patients, the Swiss drugmaker said on Friday, reversing last year's rejection.

01 Feb 2019

Novartis's cancer therapy wins UK backing after initial lymphoma snub

ZURICH Novartis's Kymriah cell therapy won the blessing of health authorities in England for adult lymphoma patients, the Swiss drugmaker said on Friday, reversing last year's rejection.

01 Feb 2019

Novartis's cancer therapy wins UK backing after initial lymphoma snub

ZURICH, Feb 1 Novartis's Kymriah cell therapy won the blessing of health authorities in England for adult lymphoma patients, the Swiss drugmaker said on Friday, reversing last year's rejection.

01 Feb 2019

Merck loses bid to revive $200 million Gilead verdict at U.S. high court

WASHINGTON The U.S. Supreme Court on Monday handed a defeat to Merck & Co by refusing to hear its appeal of a ruling that it had dishonestly obtained patent rights and could not collect a $200 million (£156.5 million) verdict against rival drugmaker Gilead Sciences Inc in a dispute involving blockbuster hepatitis C drugs.

07 Jan 2019

Merck loses bid to revive $200 million Gilead verdict at U.S. high court

WASHINGTON The U.S. Supreme Court on Monday handed a defeat to Merck & Co by refusing to hear its appeal of a ruling that it had dishonestly obtained patent rights and could not collect a $200 million verdict against rival drugmaker Gilead Sciences Inc in a dispute involving blockbuster hepatitis C drugs.

07 Jan 2019

Earnings vs. Estimates